Optimal Starting Dose of Ponatinib for Chronic Phase Chronic Myeloid Leukemia
Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Chronic Myeloid Leukemia
Review of the Cardiovascular Risks of TKI Therapy for Chronic Myeloid Leukemia
Tyrosine kinase inhibitors have improved survival outcomes for patients with CML, but these agents also have a greater risk for adverse cardiovascular events.
Tipifarnib May Yield Response in Chronic Myelomonocytic Leukemia or Other Myelodysplastic, Myeloproliferative Neoplasms
Among patients with CML, 32 were evaluable for ORR, which was determined to be 21.9%.
Dose-Optimization of Ponatinib in Patients With Resistant/Intolerant Chronic-Phase Chronic Myeloid Leukemia
Researchers sought to determine the optimal benefit/risk profile for ponatinib in patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Researchers Seek to Assess Monthly Adherence to Oral Chemotherapy Agents in Chronic Myeloid Leukemia
Researchers seek to characterize adherence trajectories, determine how side effects or financial status influence adherence, assess how adherence effects clinical outcomes, and explore unique patient perspectives.
Registry Data Support Use of Ponatinib in CML, Ph+ ALL Resistant or Intolerant to Tyrosine Kinase Inhibitors
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Safe, Successful, Even Outside Clinical Trials
A retrospective study demonstrates that TKI therapy discontinuation occurs frequently and successfully both in clinical trials and in the general population.
CML: COVID-19 May Be Fatal in More Than 5% of Patients
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
- Loading...
Loading...
Loading... 
Loading...